AR040068A1 - Inhibidores de la adhesion celular mediada por integrina alpha l beta 2 - Google Patents

Inhibidores de la adhesion celular mediada por integrina alpha l beta 2

Info

Publication number
AR040068A1
AR040068A1 ARP030100379A ARP030100379A AR040068A1 AR 040068 A1 AR040068 A1 AR 040068A1 AR P030100379 A ARP030100379 A AR P030100379A AR P030100379 A ARP030100379 A AR P030100379A AR 040068 A1 AR040068 A1 AR 040068A1
Authority
AR
Argentina
Prior art keywords
integrina
inhibitors
beta
alpha
cellular adhesion
Prior art date
Application number
ARP030100379A
Other languages
English (en)
Inventor
Ila Sircar
Marshall Morningstar
Masatoshi Kakushima
Hidefumi Kaji
Takayuki Kawaguchi
Toshiyuki Kume
Original Assignee
Tanabe Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co filed Critical Tanabe Seiyaku Co
Publication of AR040068A1 publication Critical patent/AR040068A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Obesity (AREA)

Abstract

La presente se refiere a un compuesto de fórmula (1): en la cual R es un átomo de hidrógeno, un grupo hidroxilo o un grupo carbamoilo, y n es 1 o 2, o una sal farmacéuticamente aceptable del mismo.
ARP030100379A 2002-02-07 2003-02-06 Inhibidores de la adhesion celular mediada por integrina alpha l beta 2 AR040068A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35430902P 2002-02-07 2002-02-07

Publications (1)

Publication Number Publication Date
AR040068A1 true AR040068A1 (es) 2005-03-16

Family

ID=27734354

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030100379A AR040068A1 (es) 2002-02-07 2003-02-06 Inhibidores de la adhesion celular mediada por integrina alpha l beta 2

Country Status (23)

Country Link
US (1) US7375128B2 (es)
EP (1) EP1472257B1 (es)
JP (1) JP2005517016A (es)
KR (1) KR100625379B1 (es)
CN (1) CN1301255C (es)
AR (1) AR040068A1 (es)
AT (1) ATE411995T1 (es)
AU (1) AU2003210862B2 (es)
BR (1) BR0307521A (es)
CA (1) CA2474748A1 (es)
CO (1) CO5601028A2 (es)
DE (1) DE60324250D1 (es)
EC (1) ECSP045222A (es)
MX (1) MXPA04007643A (es)
MY (1) MY137878A (es)
NO (1) NO20043563L (es)
NZ (1) NZ534208A (es)
PE (1) PE20030899A1 (es)
PL (1) PL372328A1 (es)
RU (1) RU2315768C2 (es)
TW (1) TW200303200A (es)
WO (1) WO2003066636A1 (es)
ZA (1) ZA200405647B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200407324A (en) * 2002-05-17 2004-05-16 Bristol Myers Squibb Co Bicyclic modulators of androgen receptor function
US7405234B2 (en) 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7199125B2 (en) 2003-10-02 2007-04-03 Bristol-Myers Squibb Company Spiro-cyclic compounds useful as anti-inflammatory agents
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
EP1937685A1 (en) * 2005-10-06 2008-07-02 Novartis AG Tetrahydro-pyrrolizinone compounds as lfa-i mediators
CN101638429B (zh) * 2009-08-28 2012-01-25 南方医科大学 一种特异性识别细胞表面整合素α3β1的小分子肽
US8497288B2 (en) * 2011-05-09 2013-07-30 Hoffmann-La Roche Inc. Hexahydropyrroloimidazolone compounds
EP3969066A4 (en) * 2019-05-16 2023-10-04 Dispensing Dynamics International, Inc. PERFUME DISPENSERS AND METHODS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3643748A1 (de) 1986-12-20 1988-06-30 Hoechst Ag Bicylische imide, verfahren zu ihrer herstellung sowie ihre verwendung im pflanzenschutz
PL336580A1 (en) 1997-03-03 2000-07-03 Boehringer Ingelheim Pharma Fine-molecular compounds useful in treating inflammatory diseases
WO1998058947A1 (en) 1997-06-25 1998-12-30 Pfizer Inc. Dipeptide derivatives as growth hormone secretagogues
KR100496940B1 (ko) * 1999-10-20 2005-06-23 다나베 세이야꾸 가부시키가이샤 αＬβ2 개재된 세포 접착 억제제

Also Published As

Publication number Publication date
NZ534208A (en) 2005-12-23
RU2315768C2 (ru) 2008-01-27
US20050171174A1 (en) 2005-08-04
TW200303200A (en) 2003-09-01
CO5601028A2 (es) 2006-01-31
ATE411995T1 (de) 2008-11-15
AU2003210862B2 (en) 2006-10-26
KR100625379B1 (ko) 2006-09-20
ECSP045222A (es) 2006-04-19
BR0307521A (pt) 2004-12-28
NO20043563L (no) 2004-11-01
WO2003066636A1 (en) 2003-08-14
DE60324250D1 (de) 2008-12-04
RU2004123219A (ru) 2006-02-10
CA2474748A1 (en) 2003-08-14
CN1301255C (zh) 2007-02-21
EP1472257A1 (en) 2004-11-03
MXPA04007643A (es) 2005-06-08
CN1628116A (zh) 2005-06-15
ZA200405647B (en) 2005-07-15
EP1472257B1 (en) 2008-10-22
PL372328A1 (en) 2005-07-11
PE20030899A1 (es) 2003-10-25
KR20040091625A (ko) 2004-10-28
US7375128B2 (en) 2008-05-20
AU2003210862A1 (en) 2003-09-02
JP2005517016A (ja) 2005-06-09
MY137878A (en) 2009-03-31

Similar Documents

Publication Publication Date Title
MEP13008A (en) C-aryl glucoside sglt2 inhibitors and method
DE602005016297D1 (de) Antithrombotische diamide
PT1307455E (pt) Inibidores de adesao celular mediada por (alfa)l (beta)2
FI1610780T4 (fi) Sykliset proteiinityrosiinikinaasi-inhibiittorit
TW200730540A (en) Novel peptide compounds
AR049274A1 (es) Acido2-{[2-(2-metilaminopirimidin-4-il)-1h-indol-5-carbonil]amino}-3-(fenilpiridin-2-ilamino)propionico sustancialmente puro como inhibidor selectivo de la quinasa ikk-2
MXPA03005464A (es) Agentes antivirales.
EP2374464A3 (en) HCV N3S-NS4A protease inhibition
TW200504067A (en) New substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions
AR043929A1 (es) Fases cristalinas de un inhibidor del hcv
EA011572B9 (ru) Производные хинолина для применения в качестве микобактериальных ингибиторов
DE602005019316D1 (en) Aromatische etherderivate als thrombin-hemmer
ATE341550T1 (de) Quinolinyl-pyrrolopyrazole
TW200633979A (en) Method
AR049681A1 (es) Macrolidos preparados a partir de actinomicetos. composiciones farmaceuticas
AR040068A1 (es) Inhibidores de la adhesion celular mediada por integrina alpha l beta 2
MX2007003913A (es) Alquil-piridinas como inhibidores de 11 beta para diabetes.
CY1109763T1 (el) Υλικα και μεθοδος για τη θεραπεια διαταραχων πηξης
WO2006008545A3 (en) Thiazole and isothiazole derivatives as protein kinase inhibitors
SE0302323D0 (sv) Novel compounds
WO2003106450A8 (de) Phenylaminopyrimidine und ihre verwendung als rho-kinase inhibitoren
DE602005011267D1 (de) Benzofuran- und benzothiophenderivate, die sich für die behandlung von herzkreislauferkrankungen eignen
MXPA03010766A (es) Nuevos compuestos y composiciones como inhibicores de las catepsinas.
UY28688A1 (es) Derivados de amida
ATE308540T1 (de) Antithrombosemittel

Legal Events

Date Code Title Description
FB Suspension of granting procedure